Movatterモバイル変換

Jump to content

paroxetine(Q408471)

From Wikidata

pharmaceutical drug

BRL-29060
(-)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine
(3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(−)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine

Language	Label	Description	Also known as
default for all languages	No label defined
English	paroxetine	pharmaceutical drug	BRL-29060 (-)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine (−)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine

Statements

type of chemical entity

0 references

heterocyclic compound

0 references

1 reference

Paroxetine(English)

language of work or name

publication date

17 November 2015

chemical structure

Paroxetine Structural Formulae V.1.svg
483 × 444; 15 KB

0 references

329.143dalton

1 reference

language of work or name

paroxetine(English)

19 October 2016

chemical formula

C₁₉H₂₀FNO₃

1 reference

language of work or name

paroxetine(English)

19 November 2016

canonical SMILES

C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4

1 reference

language of work or name

paroxetine(English)

19 November 2016

isomeric SMILES

C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4

1 reference

language of work or name

paroxetine(English)

19 November 2016

defined daily dose

20milligram

route of administration

oral administration

1 reference

Anatomical Therapeutic Chemical Classification System

active ingredient in

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

World Health Organisation international non-proprietary name

paroxetine(English)

1 reference

language of work or name

Paroxetine(English)

19 January 2016

medical condition treated

obsessive-compulsive disorder

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

eating disorder

1 reference

language of work or name

13 December 2016

neurotic disorder

1 reference

language of work or name

13 December 2016

1 reference

language of work or name

13 December 2016

social anxiety disorder

1 reference

language of work or name

13 December 2016

post-traumatic stress disorder

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

generalized anxiety disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

anxiety disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

nature of statement

1 reference

Possible paroxetine-zolpidem interaction.

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

solute carrier family 6 member 4

subject has role

enzyme inhibitor

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

route of administration

oral administration

0 references

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.(English)

pregnancy category

Australian pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

described at URL

https://cpe.org.uk/our-news/mhra-class-2-medicines-recall-paroxetine-40mg-film-coated-tablets-crescent-pharma-limited/

1 reference

https://cpe.org.uk/our-news/mhra-class-2-medicines-recall-paroxetine-40mg-film-coated-tablets-crescent-pharma-limited/

MHRA Class 2 Medicines Recall: Paroxetine 40mg Film Coated Tablets (Crescent Pharma Limited) - Community Pharmacy England(British English)

24 October 2024

subject has role

selective serotonin reuptake inhibitor

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

15 March 2018

cytochrome P-450 CYP2D6 inhibitors

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

second-generation antidepressive agents

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

PARoxetine

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

0 references

Commons category

Paroxetine

0 references

Identifiers

InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

1 reference

language of work or name

paroxetine(English)

19 November 2016

AHOUBRCZNHFOSL-YOEHRIQHSA-N

2 references

language of work or name

paroxetine(English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

paroxetine(English)

19 November 2016

CAS Common Chemistry

7 April 2021

https://commonchemistry.cas.org/detail?cas_rn=61869-08-7

AHOUBRCZNHFOSL-YOEHRIQHSA-N

1 reference

language of work or name

Paroxetine(English)

19 November 2016

2 references

language of work or name

paroxetine(English)

19 November 2016

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

Reaxys registry number

7467879

1 reference

language of work or name

paroxetine(English)

19 October 2016

mapping relation type

2 references

language of work or name

PAROXETINE(English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

1 reference

language of work or name

PAROXETINE(English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

UniChem compound ID

1 reference

MassBank accession ID

0 references

MSBNK-Athens_Univ-AU152606

0 references

MSBNK-Waters-WA001105

0 references

MSBNK-Waters-WA001106

0 references

MSBNK-Waters-WA001107

0 references

MSBNK-Waters-WA001108

0 references

MSBNK-Waters-WA001109

0 references

splash10-001i-2409000000-077fb077fbf0e4210f51

0 references

splash10-0006-8900000000-0a273deac3c7836cdc76

0 references

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

PAROXETINE(English)

10 May 2021

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine(English)

CAS no.: 61869-08-7(English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine(English)

CAS no.: 61869-08-7(English)

1 reference

language of work or name

Paroxetine(English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

paroxetine(English)

19 November 2016

MeSH descriptor ID

subject named as

Paroxetine

0 references

MeSH concept ID

0 references

D03.383.621.600

0 references

1 reference

Global Substance Registration System

language of work or name

paroxetine(English)

19 November 2016

1 reference

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

2 references

Global Substance Registration System

language of work or name

paroxetine(English)

19 November 2016

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

1 reference

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

paroxetine(English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

paroxetine(English)

19 October 2016

1 reference

language of work or name

paroxetine(English)

19 October 2016

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

PDB structure ID

1 reference

Protein Data Bank

PDB structure ID

language of work or name

5I6X(English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3V5W(English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4JLT(English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4MM4(English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4L9I(English)

19 October 2016

UK Parliament thesaurus ID

subject named as

Paroxetine

0 references

1 reference

Global Substance Registration System

language of work or name

paroxetine(English)

19 November 2016

WikiProjectMed ID

0 references

WordNet 3.1 Synset ID

03897548-n

1 reference

Sitelinks

Wikipedia(32 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswikiCategory:Paroxetine

Retrieved from "https://www.wikidata.org/w/index.php?title=Q408471&oldid=2294989290"

[8]ページ先頭

©2009-2025 Movatter.jp